VESALIUS-CV

Sustained Cardiovascular Protection With Evolocumab in Patients Without Prior MI or Stroke: Insights From the VESALIUS-CV Trial

Evolocumab significantly reduces first and subsequent major adverse cardiovascular events in high-risk patients without prior myocardial infarction or stroke, affirming the benefit of intensive LDL-C lowering for cumulative cardiovascular r